Evidence map›Paper›PMID 39123487›Full record

ArticleCancers2024

Prediction of PSA Response after Dexamethasone Switch during Abiraterone Acetate + Prednisolone Treatment of Metastatic Castration-Resistant Prostate Cancer Patients.

Bertalan Fekete, Krisztina Biró, Fruzsina Gyergyay, Nándor Polk, Orsolya Horváth, Lajos Géczi, Attila Patócs, Barna Budai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bertalan FeketeDepartment of Endocrinology and Diabetology, Internal Medicine II, Central Hospital of Northern Pest-Military Hospital, Podmaniczky u. 109-111, 1062 Budapest, Hungary.
Krisztina BiróDepartment of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
Fruzsina GyergyayDepartment of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
Nándor PolkDepartment of Visceral Surgery, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
Orsolya HorváthDepartment of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
Lajos GécziDepartment of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.ORCID 0009-0002-9538-0829
Attila PatócsNational Tumor Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.ORCID 0000-0001-7506-674X
Barna BudaiDepartment of Molecular Genetics, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy 7-9, 1122 Budapest, Hungary.ORCID 0000-0001-9411-9202

Funding

National Research, Development and Innovation Office 2022-2.1.1-NL-2022-00010 and TKP2021-EGA-44
6 · The paper itself

Abstract

backgroundThe aim was to elaborate a predictive model to find responders for the corticosteroid switch (from prednisolone to dexamethasone) at the first prostate-specific antigen (PSA) progression (≥25% increase) during abiraterone acetate (AA) treatment of metastatic castration-resistant prostate cancer (mCRPC) patients.

methodsIf PSA has decreased (≥25%) after switch, patients were considered responders. Logistic regression of 19 dichotomized parameters from routine laboratory and patients' history was used to find the best model in a cohort of 67 patients. The model was validated in another cohort of 42 patients.

resultsThe model provided 92.5% and 90.5% accuracy in the testing and the validation cohorts, respectively. Overall the accuracy was 91.7%. The AUC of ROC curve was 0.92 (95% CI 0.85-0.96). After a median follow-up of 27.9 (26.3-84) months, the median AA+dexamethasone treatment duration (TD) in non-responders and responders was 4.7 (3.1-6.5) and 11.1 (8.5-12.9) months and the median overall survival (OS) was 23.2 (15.6-25.8) and 33.5 (26.1-38) months, respectively. Multivariate Cox regression revealed that responsiveness was an independent marker of TD and OS.

conclusionsA high accuracy model was developed for mCRPC patients in predicting cases which might benefit from the switch. For non-responders, induction of the next systemic treatment is indicated.

Indexed as

corticosteroid switchoverall survivalpredictive modelresponderstreatment duration

Identifiers

PMID39123487
PMCPMC11311488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.